

Grifols announces €500m redemption of 7.5% 2030 bonds to further optimize its capital structure

- *Proactive partial redemption of highest-cost debt would reduce cash interest expense and funded gross debt levels*
- *Following the closing of its highly successful refinancing, Grifols will have no debt maturities until October 2028*
- *Grifols intends to continue to maintain strong liquidity levels*

Barcelona, Spain, April 13, 2026 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, plans to redeem €500 million of its 7.5% Senior Secured Notes due 2030, which would reduce the outstanding amount of its highest-cost indebtedness as part of an ongoing strategy to reduce cash interest expense and strengthen its capital structure.

The partial redemption of 7.5% Senior Secured 2030 Notes would follow Grifols' previously announced successful loan syndication and planned refinancing of its 2027 debt maturities, which includes a Secured Term Loan B that was significantly upsized to approximately €3 billion (equivalent) and an approximately \$2 billion Secured Revolving Credit Facility. The syndication was supported by strong global investor demand and institutional backing. Following the closing of the refinancing, scheduled for April 14, Grifols will have no material debt maturities until October 2028. Together these proactive actions will strengthen the company's balance sheet by reducing funded gross debt levels, lowering cash interest expense, improving its debt maturity profile, while maintaining strong liquidity levels.

Rahul Srinivasan, CFO of Grifols, said: "This is a further step forward in the execution of our financial strategy. By proactively redeeming our highest-cost debt, we will reduce our cash interest expense and further strengthen our balance sheet, while continuing to maintain strong liquidity levels."

The closing of the new loan financing, which is subject to customary closing conditions, is a condition for the partial redemption of the 7.5% Senior Secured Notes due 2030 as well as the refinancing of the Company's debt instruments which mature in 2027.

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols focuses on treating conditions centered on six core therapeutic areas: immunology, neurology, pulmonology, hematology, hepatology and intensive care.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's most diversified with more than 400 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 25,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the IBEX-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com

MEDIA CONTACTS:

Grifols Press Office

media@grifols.com

Tel. +34 93 571 00 02

INVESTORS:

Investor Relations & Sustainability

inversores@grifols.com - investors@grifols.com

sostenibilidad@grifols.com – sustainability@grifols.com

Tel. +34 93 571 02 21

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are 'projections and future hypotheses'. Words and expressions such as 'believe', 'expect', 'anticipate', 'predict', 'hope', 'intend', 'should', 'will try to achieve', 'is estimated', 'future' and similar expressions, insofar as they refer to the Grifols group, are used to identify future projections and hypotheses. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a series of factors that mean that the real results may be materially different. The future results of the Grifols group could be affected by events related to its own activities, such as shortages of supplies of raw materials for the manufacture of its products, the appearance on the market of competing products, or changes in the regulatory framework of the markets in which it operates, among others. At the date of preparation of this report, the Grifols group has adopted the necessary measures to mitigate the foreseeable impact of these events. Grifols, S.A. assumes no obligation to publicly report, revise or update the projections or future hypotheses to adapt them to facts or circumstances after the date of writing of this report, except when expressly required by applicable legislation. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Law 6/2023, of 17 March, on the Securities Markets and Investment Services, and any regulations implementing said legislation. Furthermore, this document does not constitute an offer to purchase, sell or exchange, or a solicitation of an offer to purchase, sell or exchange any securities, or a solicitation of any vote or approval in any other jurisdiction. The information contained in this document has not been verified or revised by the external auditors of the Grifols group.